Loading...
Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine
Treatment of permissive tumors with the oncolytic virus (OV) VSV-Δ51 leads to a robust antitumor T-cell response, which contributes to efficacy; however, many tumors are not permissive to in vivo treatment with VSV-Δ51. In an attempt to channel the immune stimulatory properties of VSV-Δ51 and broade...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3437573/ https://ncbi.nlm.nih.gov/pubmed/22760544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2012.128 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|